NTLA Stock Overview
A genome editing company, focuses on the development of curative therapeutics. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Intellia Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.12 |
| 52 Week High | US$34.87 |
| 52 Week Low | US$12.82 |
| Beta | 1.81 |
| 11 Month Change | -36.53% |
| 3 Month Change | -42.96% |
| 1 Year Change | -56.64% |
| 33 Year Change | -88.64% |
| 5 Year Change | -22.85% |
| Change since IPO | -40.63% |
Recent News & Updates
Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)
Nov 19Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus
Nov 11Data Underwhelms - Intellia's Cash, Data And Competition Are A Challenging Story
Nov 05Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity
Oct 25Recent updates
Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)
Nov 19Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus
Nov 11Data Underwhelms - Intellia's Cash, Data And Competition Are A Challenging Story
Nov 05Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity
Oct 25Intellia - Exciting Promise Of First In-Vivo Gene Therapy Makes Bull Case
Sep 25We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate
Sep 07
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 11Intellia Therapeutics Is Expanding The Scope Of Gene Editing (Technical Analysis)
Aug 03Here's Why It's Unlikely That Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO Will See A Pay Rise This Year
Jun 06Intellia Therapeutics Presents Promising In Vivo CRISPR Results
Jun 05Industry Analysts Just Made A Dazzling Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts
May 14Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies
May 13Intellia Therapeutics Is On The Move
Feb 29Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 24Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier
Feb 09Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?
Feb 07Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?
Jan 01Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans
Oct 20Intellia Therapeutics: Top Speculative Trade In The Biotech Space
Oct 05Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling
Sep 01Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?
Aug 06Intellia Therapeutics down 12% following bottom line Q2 earnings miss
Aug 04Intellia: Slim Hopes Of Near-Term Commercial Revenue Makes Me Bearish
Jul 28Intellia Therapeutics: Several Catalysts Expected For H2 2022
May 12Intellia: One Patent Ruling Turns The Industry Upside Down
Mar 09Intellia Therapeutics: A Lot Of News Can Bring The Stock Up
Feb 25Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022
Feb 09Intellia: Best All-Around Gene Editing Company
Jan 27We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth
Dec 31Intellia Has Potential As Gene Therapy Play With Second Product Being Tested In Humans
Dec 15Intellia Stock: Setting Up For Success
Nov 29Intellia: A Step Closer To A Life-Changing Cure
Nov 21Shareholder Returns
| NTLA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -18.6% | -6.5% | -1.0% |
| 1Y | -56.6% | 14.6% | 30.3% |
Return vs Industry: NTLA underperformed the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: NTLA underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| NTLA volatility | |
|---|---|
| NTLA Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NTLA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NTLA's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 526 | John Leonard | www.intelliatx.com |
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases.
Intellia Therapeutics, Inc. Fundamentals Summary
| NTLA fundamental statistics | |
|---|---|
| Market cap | US$1.44b |
| Earnings (TTM) | -US$522.28m |
| Revenue (TTM) | US$43.09m |
31.0x
P/S Ratio-2.6x
P/E RatioIs NTLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NTLA income statement (TTM) | |
|---|---|
| Revenue | US$43.09m |
| Cost of Revenue | US$458.42m |
| Gross Profit | -US$415.33m |
| Other Expenses | US$106.96m |
| Earnings | -US$522.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.13 |
| Gross Margin | -963.95% |
| Net Profit Margin | -1,212.19% |
| Debt/Equity Ratio | 0% |
How did NTLA perform over the long term?
See historical performance and comparison